Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Prana Biotechnology Investor Presentation

June 27, 2018 Kerry Rowe

1_Prana Biotechnology Investor Presentation_2018-0627 final

Post navigation

Prana to commence Phase 1 clinical trial of PBT434 for treatment of parkinsonian diseases

First volunteers dosed in Phase I clinical trial of PBT434, Prana’s lead therapy for parkinsonian diseases

Related Posts

Alterity Therapeutics AAN Presentation 5 May 2019

May 6, 2019May 27, 2019

Notice of General Meeting 2019

March 13, 2019

Alterity to present at the 7th International Congress of Multiple System Atrophy

February 26, 2021May 19, 2021

Recent Posts

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
Alterity to Present at Life Sciences Investor Forum
Alterity Therapeutics to Present at the GCFF Virtual Conference 2022 – Investing in Healthcare
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065